Navigation Links
Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
Date:11/17/2010

HORSHAM, Pa., Nov. 17, 2010 /PRNewswire/ -- Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, today announced that Bob Radie has been appointed President and Chief Executive Officer (CEO).  Thomas Beck, M.D., who was serving as interim Chief Executive Officer, will resume his role as Chief Medical Officer of the company.

Topaz Pharmaceuticals' lead product, ivermectin topical cream, is concluding Phase 3 clinical trials to support a new drug application for the treatment of head lice.  

"Bob's appointment follows a comprehensive selection process by the Board of Directors to identify the best leader to take Topaz Pharmaceuticals forward and maximize the value of its lead product, a novel formulation of ivermectin," said Robert D. Casale, non-executive Chairman of the Board.  "Bob's combination of business development experience as well as his expertise in successfully introducing new medicines into the commercial market is a great fit for Topaz as we prepare to report Phase 3 data on ivermectin topical cream for the treatment of head lice.  Bob's extensive pharmaceutical experience should prove highly beneficial to Topaz as the company continues to advance this novel product through the drug approval process."

Mr. Radie has over 25 years of experience in the pharmaceutical and biotechnology industries.  Most recently, he served as President and CEO of TransMolecular, Inc., a biotechnology company developing novel cancer diagnostic and treatment products.  He previously served as Chief Business Officer at Prestwick Pharmaceuticals, Inc. and Morphotek.  He played leading roles in the acquisition of Prestwick by Biovail Corp. in 2008 and Morphotek by Eisai, Inc. in 2007.  He has also served as senior vice president of strategic projects and planning at Vicuron Pharmaceuticals (acquired in 2005 by Pfizer).  Before joining Vicuron, Mr. Radie worked for Eli Lilly and Company, where he led several different sales forces and played a key role in numerous product launches.  Among the flagship products he successfully launched were Prozac®, Zyprexa® and Actos®.  Mr. Radie holds a Bachelor of Science degree in chemistry from Boston College.

"I am honored to join the team at Topaz as we advance a promising late-stage development product targeted for the treatment of head lice, a common condition that affects millions of children.  There is a true need for effective, safe and convenient treatment options for eradication of head lice," said Radie.  "Ivermectin has a long history of productive use for the treatment of other parasitic infections.  Studies conducted to date in this development program have shown very promising results.  I look forward to partnering with the team and Board of Directors as we propel Topaz to the next phase of commercial growth and optimizing the value of the asset."

About Ivermectin

Ivermectin is a broad-spectrum antiparasitic agent.  Its known mechanism of action is that it binds selectively to certain ion channels present in invertebrate nerve and muscle cells but not present in mammals. The resulting increase in permeability of the cell membrane causes the death of certain parasites.  First developed from a soil bacterium, widespread oral use of ivermectin, under the brand name Mectizan®, began in 1987 in sub-Saharan Africa to control onchocerciasis (river blindness) in humans.  As of 2009, over 800 million doses of oral ivermectin had been administered as part of a river blindness eradication program.(1)  A novel topical form of ivermectin is currently under clinical investigation at Topaz as a potential therapy to treat head lice. 

About Topaz Pharmaceuticals

Topaz Pharmaceuticals Inc. is a privately held specialty pharmaceutical company developing innovative treatments for the adult and pediatric markets. The company's lead investigational product is a topical cream formulation of ivermectin, a broad spectrum parasiticide, under development for the treatment of head lice. The company is conducting two Phase 3 studies of ivermectin for this potential indication. For more information about Topaz Pharmaceuticals Inc., please visit www.topazpharma.com.

Mectizan® is a registered trademark of Merck & Company.

Prozac® is a registered trademark of Eli Lilly and Company.

Zyprexa® is a registered trademark of Eli Lilly and Company.

Actos® is a registered trademark of Takeda Pharmaceutical Company Limited.

Reference:

  1. Moreno Y, Nabhan JF, Solomon J, Mackenzie CD, Geary TG.  Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi. Proceedings of the National Academy of Science, 2010;Published on line, www.pnas.org/cgi/doi/10.1073/pnas.1011983107.


'/>"/>
SOURCE Topaz Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TOPAZ Technologies and ML Weekes & Company Announce Partnership
2. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
3. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
4. TOPAZ Technologies and Tecniplast USA Launch RFID Mobile Census
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
8. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
10. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
11. Vanda Pharmaceuticals Appoints Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... 11, 2017  Thornhill Research Inc. ( ... an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by ... Commercial Corporation (CCC) ( Ottawa, Ontario, Canada ... administer general anesthesia to patients requiring emergency medical ... US Marine Corps have been a longtime partner ...
(Date:5/10/2017)... 10, 2017 Global Health Intelligence (GHI), ... America , published its 2017 ranking of the ... on extensive data analysis from GHI,s hospitals database for ... for the region. The GHI database covers 86% of the ... than 130 data points for each institution in key areas ...
(Date:5/10/2017)... May 10, 2017 Radiology has become the ... costs have also spiraled to the number one ranking ... radiology than ever before as the most complete and ... patient with lower back pain an MRI may confirm ... for pain, resulting in entirely different treatment protocols.  In ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Boar’s Head Brand®, one of the ... Day entertaining that are sure to satisfy your guests’ flavor cravings, while adding ... cheeses featured in these refreshingly balanced recipes are packed with flavor, creating the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... is focusing on the Peace Agreements being discussed by President Donald Trump and the ... race to try to speed up peace talks in the continuous battle between Israel ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: ... the creation of published author Laura Weigel Douglas, an avid reader who lives in ... house that sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “Cactus Jack: ... had on so many others. “Cactus Jack: Against All Odds” is the creation ... Walter D. Hubbard is married to Jack Carlisle’s third child Jane. Walter. ...
(Date:5/24/2017)... ... 2017 , ... Dr. Alan I. Benvenisty, MD is dual board certified in ... known for his distinguished expertise and experience in the diagnosis and treatment of vascular ... treating renovascular disease and aortic aneurysm . He is known for his minimally ...
Breaking Medicine News(10 mins):